Literature DB >> 2870087

The natural course of schizophrenia and effective maintenance drug treatment.

J M Davis, S Andriukaitis.   

Abstract

The natural course of schizophrenia is poor; in the absence of consistently effective and broadly applied treatment, about two thirds of schizophrenic patients remain symptomatic. Antipsychotic drugs dramatically improve the prognosis of these patients, and there is limited evidence that the use of these drugs during an acute episode may improve a patient's long-term outcome. Continued administration of antipsychotic drugs significantly attenuates the relapse rate among schizophrenic patients; however, compliance with oral antipsychotic medication remains a problem in this population. Long-acting depot antipsychotic drugs have an obvious advantage in improving patient compliance, and there are some data that suggest that relapse rates may be lower in patients receiving depot drugs compared with oral drugs. Because of the greater assurance long-acting depot drugs provide about medication compliance, these drugs clearly have a significant role in the maintenance treatment of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870087

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

1.  Effects of capitation on health of the chronically ill. Implications for antipsychotic drug therapy.

Authors:  S K Reed; K Maharaj
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 2.  Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.

Authors:  Robert C Smith; Stefan Leucht; John M Davis
Journal:  Psychopharmacology (Berl)       Date:  2018-11-30       Impact factor: 4.530

3.  Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective.

Authors:  Jeffrey A Lieberman
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Depot haloperidol decanoate for schizophrenia.

Authors:  S Quraishi; A David
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 6.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 7.  Depot pipotiazine palmitate and undecylenate for schizophrenia.

Authors:  M Dinesh; A David; S N Quraishi
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 8.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

Review 9.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

10.  Conventional and atypical antipsychotics in the elderly : a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Mariagrazia Stilo; Guido Ferreri; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.